Virginia Powers | Authors

March 17, 2017

Inhibition of CDK4/6 results in improvements in progression-free survival in women with estrogen receptor ER-positive HER2-negative metastatic breast cancer whether it is endocrine sensitive or resistant.

February 06, 2017

Several subtypes of difficult-to-treat sarcomas may respond to treatment with PD-1 pathway inhibiting immunotherapies, according to findings of an immunohistochemistry analysis of a large patient population.

February 02, 2017

Patients receiving the same diagnosis, colorectal cancer with synchronous peritoneal metastases (PM), were offered different treatments that led to dramatically different outcomes based upon the institution in which they were diagnosed.

February 02, 2017

Treatment with the PD-1 inhibitor pembrolizumab significantly prolonged overall survival over investigators’ choice of chemotherapy in patients with recurrent advanced urothelial carcinoma.

February 02, 2017

The incidence of hand-foot syndrome occurred significantly less often in patients treated with S-1 compared to capecitabine in patients with metastatic colorectal cancer.

February 02, 2017

A pre-planned subgroup analysis of data from the MONALEESA-2 trial demonstrated similar clinical benefit and safety profiles in elderly patients compared to younger patients with HR+/HER2-advanced breast cancer, supporting a paradigm shift in the future medical management of these patients from the current standard of letrozole to combined treatment of letrozole plus ribociclib.